The Patent Finder

Celldex Therapeutics, Inc.

25 patents currently held · Updated Nov 15, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 27, 2027
    The maintenance fee for Use of ANTI-PD-1 Antibody in Combination with ANTI-CD27 Antibody in Cancer Treatment (US 10,392,442) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
  • 1 fee due Apr 27, 2027
    The maintenance fee for Antibodies that bind human CD27 and uses thereof (US 9,169,325) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
  • 2 fees due Jul 30, 2027
  • 1 fee due Aug 6, 2027
    The maintenance fee for Anti-kit antibodies and uses thereof (US 11,891,452) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
  • 1 fee due Sep 29, 2027
    The maintenance fee for Treatment of Chronic Nephropathies Using Soluble Complement Receptor Type I (SCR1) (US 9,295,713) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
  • 2 fees due Oct 23 to 28, 2027 · next Oct 23
  • 1 fee due Nov 10, 2027
    The maintenance fee for Anti-kit antibodies (US 9,334,332) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,649,357Treatment Of Chronic Nephropathies Using Soluble Complement Receptor Type I (sCR1)
In force
 · High confidence
In forceHigh confidence
US 10,189,907Polynucleotides encoding anti-KIT antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,793,639Methods of treating by administering anti-kit antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,884,699Anti-KIT antibodies and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,295,713Treatment of Chronic Nephropathies Using Soluble Complement Receptor Type I (SCR1)
In force
 · High confidence
In forceHigh confidence
US 9,605,081Polynucleotides encoding anti-kit antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,184,007Methods of treating a kit-associated cancer by administering anti-kit antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,781,267Methods of treating by administering anti-kit antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,334,332Anti-kit antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,169,325Antibodies that bind human CD27 and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 25 patents shown.
Pro members see all 25.
Pro members: see all 25 patents
Also on record, not counted in the 25: 1 patent in force now held by others · 49 lapsed for an unpaid fee · 27 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 pending · 14 abandoned · 18 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited